MedPath

Intra-procedural Transthoracic EChocardiogram to Facilitate Left Bundle Branch Area Pacing (LBBAP)

Not Applicable
Completed
Conditions
Heart Failure
Registration Number
NCT05646251
Lead Sponsor
Geisinger Clinic
Brief Summary

The goal of this observational study is to learn more about whether or not the use of heart ultrasound during pacemaker implantation is helpful. The main questions this aims to answer are:

1. Does this help the doctors with figuring out the wire location during implantation?

2. Does this reduce the wire placement procedure time?

3. Does this reduce the x-ray imaging time during the procedure?

Participants will be asked to:

1. Have a physical exam and Echocardiogram (ECG) at initial visit, 2 weeks post implant, and 3 months post implant.

2. Have a urine pregnancy test (if applicable)

3. Have a heart ultrasound during implant procedure

4. Answer questions related to heart failure symptoms to see what stage of heart failure is present

5. Have device interrogation (a wand placed over the chest to see that the device is working properly) at a visit 2 weeks post implant and at 3 months post implant.

Detailed Description

The EC-LBBAP study is a prospective, single-enter, observational research study. The study team will identify all patients who satisfy the inclusion and exclusion criteria. The study team will evaluate the feasibility and success rates of echocardiogram guided LBBAP lead implantation.

Eligible patients will undergo LBBAP using Medtronic 3830 lead and C315His sheath. LBBAP will be confirmed at implant using left bundle potentials recorded from the lead, ECG morphology during unipolar and bipolar pacing, peak Left Ventricular Pacing (LV) activation time and lead depth in the 2D transthoracic echo at implant.

During implant procedure, transthoracic echo windows will be identified and documented: Parasternal short and long axis, apical 2 and 4 chamber views and subcostal views to visualize the proximal interventricular septum. Following venous access using cephalic vein cut-down or ultrasound guided axillary vein access, the lead implantation in the left bundle branch region will be guided by echocardiography.

Retrospectively, the study team will identify 20 consecutive previous patients who satisfy inclusion and exclusion criteria (control patients). Twenty patients will undergo intraprocedural transthoracic echocardiogram via standard practices. An additional 10 patients will undergo intraprocedural transthoracic echocardiogram using a hand-held ultrasound device. The study team will compare the difference in procedural success between case and control patients.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
33
Inclusion Criteria
  • patient with indication for permanent pacemaker or Implantable Cardioverter Defibrillator (ICD) utilizing conduction system pacing lead for bradycardia or cardiac resynchronization therapy
  • patient is willing to comply with all study procedures and be available for the duration of the study
Exclusion Criteria
  • Inability to provide informed consent
  • pregnant
  • enrolled in a concurrent study that may confound the results of this study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
A Positive Success Rate of LBBAP Utilization With Intraprocedural Transthoracic EchocardiogramPerioperative, through study completion, an average of 3 months

Positive success rate of LBBAP is measured by Left bundle branch capture for participants, measured during implant

Difference of Fluoroscopy/Procedure Duration Between GroupsPerioperative

Difference in fluoroscopy and procedure duration using echo guided LBBAP lead implantation compared to control data for standard LBBAP lead implantation

Number of Participants Determined to be Eligible for the Work-flow and Echocardiographic ProceduresThrough study completion, an average of 3 months

This measure is to determine if the workflow is feasible in regular practice (echo tech availability, lab availability, duration of comparative procedures) between intervention group and controls, and to determine if the identifying echocardiographic windows is able to be performed pre operatively on all intervention patients

This measure is to determine the number of participants that the workflow is feasible for and could be performed on in regular practice (echo tech availability, lab availability, duration of comparative procedures)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Geisinger Clinic

🇺🇸

Wilkes-Barre, Pennsylvania, United States

Geisinger Clinic
🇺🇸Wilkes-Barre, Pennsylvania, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.